Kết quả điều trị bệnh nhân Parkinson bằng levodopa kết hợp pramipexole tại Bệnh viện Đa khoa Trung ương Cần Thơ

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Tiến Đạt Diệp, Văn Minh Lê

Ngôn ngữ: Vie

Ký hiệu phân loại:

Thông tin xuất bản: Y Dược học Cần Thơ 2023

Mô tả vật lý: 45299

Bộ sưu tập: Metadata

ID: 407602

Thêm vào giỏ Liên kết toàn văn

Tóm tắt
Chủ đề

Mô tả các triệu chứng lâm sàng và đánh giá kết quả điều trị của levodopa kết hợp pramipexole trên bệnh nhân Parkinson. Đối tượng và phương pháp nghiên cứu: 61 bệnh nhân Parkinson đến khám và điều trị tại Bệnh viện Đa khoa Trung ương Cần Thơ trong thời gian từ 3/2021 đến 5/2022 được đánh giá các triệu chứng vận động, ngoài vận động, thang điểm UPDRS và thang điểm PDQ-39 lúc chưa điều trị và sau khi điều trị bằng levodopa kết hợp pramipexole. Kết quả: Tuổi trung bình mắc bệnh là 65±5,15. Điểm UPDRS lúc nhập viện 26,6±12,36, điểm PDQ-39 lúc nhập viện 50,8±16,2. Các triệu chứng vận động chủ yếu là chậm vận động (96,72%), cứng cơ, bánh xe răng cưa (96,72%) và run khi nghỉ (95,08%). Các triệu chứng ngoài vận động chủ yếu là đau, rối loạn cảm giác (93,44%), rối loạn thần kinh tự chủ (93,44%). Liệu pháp phối hợp levodopa và pramipexole giúp cải thiện điểm UPDRS phần I, II và III và điểm PDQ-39 có ý nghĩa thống kê (p<
0,05). Kết luận: Điều trị bằng levodopa kết hợp pramipexole giúp cải thiện các triệu chứng lâm sàng và chất lượng cuộc sống của bệnh nhân Parkinson biểu hiện thông qua sự cải thiện điểm UPDRS và điểm PDQ-39., Tóm tắt tiếng anh, Parkinson's disease is known for its group of motor symptoms and nonmotor symptoms that cause disability and negatively affect the patient's quality of life. Early diagnosis and appropriate treatment to minimize the negative effects of the disease and drug side effects on the patient. Objective: To describe the clinical symptoms and evaluation of the results of levodopa combined with pramipexole in the treatment of Parkinson's disease. Material and method: 61 individuals with Parkinson's disease admitted to Can Tho Central General Hospital from March 2021 to May 2022 investigate motor symptoms, non-motor symptoms, UPDRS scores, and PDQ-39 scores at untreated and after levodopa combined pramipexole therapy. Results: The mean age of disease was 65±5.15. Common motor symptoms were dyskinesia (96.72%), muscle stiffness, cogwheel (96.72%), and tremor (95.08%). Common non-motor symptoms were pain, sensory disturbance (93.44%), and autonomic dysfunction (93.44%). Combination therapy of levodopa and pramipexole resulted in statistically significant improvements in the UPDRS part I, II, and III scores and PDQ-39 scores (p<
0.05). Conclusion: Treatment with levodopa combined with pramipexole improves clinical symptoms and quality of life in Parkinson's patients, through an improvement in the UPDRS score and PDQ-39 score

Tạo bộ sưu tập với mã QR